Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bimekizumab versus placebo in moderate to severe hidradenitis suppurativa
jRCT2080225271Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Bimekizumab with Placebo (2 arms). Primary endpoint: Primary endpoint not reported in provided registry extract. Started Jul 2020; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2080225271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225271.